Long-term effects of dalfampridine in patients with multiple sclerosis

Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment par...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of the neurological sciences Ročník 337; číslo 1-2; s. 18 - 24
Hlavní autoři: Ruck, T., Bittner, S., Simon, O.J., Göbel, K., Wiendl, H., Schilling, M., Meuth, S.G.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 15.02.2014
Témata:
4-Aminopyridine - therapeutic use
Cognition Disorders - drug therapy
Cognition Disorders - etiology
Dalfampridine
Disability Evaluation
Drug Delivery Systems
Electroencephalography
Evoked Potentials - drug effects
Evoked Potentials - physiology
Fatigue
Female
Follow-Up Studies
Humans
Long-term treatment
Male
Middle Aged
Mobility
Multiple Sclerosis - complications
Multiple Sclerosis - drug therapy
Neurology
Potassium Channel Blockers - therapeutic use
Severity of Illness Index
Statistics, Nonparametric
Time Factors
Walking - physiology
Walking ability
Mobility
Fatigue
Dalfampridine
Long-term treatment
MS
Walking ability
ISSN:0022-510X, 1878-5883, 1878-5883
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Dalfampridine is the extended-release formulation of 4-aminopyridine and is approved for the symptomatic treatment of impaired mobility in patients with multiple sclerosis. Our aim was to examine the short- and long-term effects of treatment with dalfampridine on motoric and cognitive assessment parameters of multiple sclerosis (MS) patients over 9–12months. Fifty-two patients with MS with an EDSS between 4.0 and 7.0 and impaired mobility were evaluated for parameters of walking ability, MSFC, cognitive and motor fatigue and evoked potentials at treatment initiation with dalfampridine as well as 2weeks and after 9–12months later. Thirty out of fifty-two patients (~60%) were still on treatment after 9–12months. Two weeks after treatment initiation, significant ameliorations could be found for T25FW, maximum walking distance as well as motoric and cognitive fatigue which still persisted after 9–12months. In contrast significant effects for velocity were observed only after 2weeks, for improvement in PASAT only after 9–12months. A tendency for improvement of somatosensory evoked potentials was found in a subset of patients. Dalfampridine shows positive short- and long-term effects on motoric and cognitive assessment parameters in an open-label observational study in a cohort of patients with MS.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0022-510X
1878-5883
1878-5883
DOI:10.1016/j.jns.2013.11.011